| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
21,020,000 |
| Market
Cap: |
15.34(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$0.625 - $8.06 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Vincerx Pharma is a clinical-stage biopharmaceutical company focused on utilizing its development and oncology capabilities to advance therapies intended to address unmet medical needs for the treatment of cancer. The small molecule drug program includes VIP152, which is a selective, clinical-stage positive transcription elongation factor beta/cyclin-dependent kinase 9 inhibitor. Co.'s antibody-drug conjugate (ADC) platform includes VIP943 and VIP924, which are ADC compounds addressing known oncology targets. The bioconjugation program also includes VIP236, which is a small molecule drug conjugate for solid tumors.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
54,276 |
234,494 |
| Total Buy Value |
$0 |
$0 |
$50,813 |
$281,100 |
| Total People Bought |
0 |
0 |
4 |
6 |
| Total Buy Transactions |
0 |
0 |
6 |
14 |
| Total Shares Sold |
0 |
0 |
0 |
0 |
| Total Sell Value |
$0 |
$0 |
$0 |
$0 |
| Total People Sold |
0 |
0 |
0 |
0 |
| Total Sell Transactions |
0 |
0 |
0 |
0 |
| End Date |
2024-01-28 |
2023-10-27 |
2023-04-28 |
2022-04-28 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Seelenberger Alexander A. |
See Remarks |
• – – |
2023-08-11 |
4 |
B |
$0.95 |
$9,968 |
D/D |
10,500 |
30,280 |
0.01 |
-31% |
|
| Hamdy Ahmed Md |
See Remarks |
• • – |
2023-08-10 |
4 |
B |
$0.96 |
$5,167 |
I/I |
5,400 |
96,060 |
0.01 |
-35% |
|
| Izumi Raquel E. |
See Remarks |
• • – |
2023-08-10 |
4 |
B |
$0.93 |
$3,199 |
I/I |
3,440 |
85,214 |
0.01 |
-35% |
|
| Thomas Tom C |
See Remarks |
• – – |
2023-08-10 |
4 |
B |
$0.95 |
$4,750 |
D/D |
5,000 |
219,935 |
0.01 |
-35% |
|
| Hamdy Ahmed Md |
See Remarks |
• • – |
2023-08-09 |
4 |
B |
$0.95 |
$15,994 |
I/I |
16,900 |
90,660 |
0.01 |
-33% |
|
| Izumi Raquel E. |
See Remarks |
• • – |
2023-08-09 |
4 |
B |
$0.90 |
$11,735 |
I/I |
13,036 |
81,774 |
0.01 |
-33% |
|
| Izumi Raquel E. |
See Remarks |
• • – |
2022-12-14 |
4 |
B |
$0.88 |
$25,427 |
I/I |
28,738 |
68,738 |
2.66 |
47% |
|
| Thomas Tom C |
See Remarks |
• – – |
2022-12-14 |
4 |
B |
$0.83 |
$5,810 |
I/I |
7,000 |
10,000 |
1.99 |
47% |
|
| Hamdy Ahmed Md |
Chief Executive Officer |
• • – |
2022-12-14 |
4 |
B |
$0.87 |
$30,538 |
I/I |
35,280 |
73,760 |
2.66 |
47% |
|
| Lowe Christopher P. |
Director |
– • – |
2022-08-25 |
4 |
B |
$1.65 |
$19,139 |
D/D |
11,600 |
40,000 |
2.39 |
-41% |
|
| Lowe Christopher P. |
Director |
– • – |
2022-08-24 |
4 |
B |
$1.65 |
$30,299 |
D/D |
18,400 |
28,400 |
2.39 |
-38% |
|
| Izumi Raquel E. |
See Remarks |
• • – |
2022-06-27 |
4 |
B |
$1.41 |
$56,312 |
I/I |
40,000 |
40,000 |
2.66 |
-30% |
|
| Hamdy Ahmed Md |
Chief Executive Officer |
• • – |
2022-06-23 |
4 |
B |
$1.41 |
$34,137 |
I/I |
24,200 |
38,480 |
2.66 |
-26% |
|
| Bushnell Laura I. |
Director |
– • – |
2022-06-09 |
4 |
B |
$1.91 |
$28,625 |
D/D |
15,000 |
19,202 |
2.39 |
-42% |
|
| Rosen David Efraim |
10% Owner |
– – • |
2022-01-20 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
2,107,000 |
|
-76% |
|
| Hwang Sooin |
Chief Business Officer |
• – – |
2021-12-23 |
4 |
B |
$10.00 |
$30,000 |
D/D |
3,000 |
390,491 |
2.74 |
-73% |
|
| Seelenberger Alexander A. |
Chief Financial Officer |
• – – |
2021-12-22 |
4 |
B |
$10.34 |
$24,988 |
D/D |
2,417 |
12,493 |
2.74 |
-74% |
|
| Bushnell Laura I. |
Director |
– • – |
2021-12-22 |
4 |
B |
$10.48 |
$25,173 |
D/D |
2,402 |
4,202 |
2.39 |
-74% |
|
| Thomas Tom C |
See Remarks |
• – – |
2021-12-22 |
4 |
B |
$10.23 |
$10,230 |
I/I |
1,000 |
3,000 |
1.99 |
-74% |
|
| Hamdy Ahmed Md |
Chief Executive Officer |
• • – |
2021-12-22 |
4 |
B |
$10.02 |
$64,650 |
I/I |
6,450 |
14,280 |
2.66 |
-74% |
|
| Izumi Raquel E. |
See Remarks |
• • – |
2021-08-04 |
4 |
B |
$11.96 |
$11,960 |
I/I |
1,000 |
1,000 |
2.58 |
-18% |
|
| Bushnell Laura I. |
Director |
– • – |
2021-06-30 |
4 |
B |
$12.94 |
$23,297 |
D/D |
1,800 |
1,800 |
2.39 |
11% |
|
| Hwang Sooin |
Chief Business Officer |
• – – |
2021-06-30 |
4 |
B |
$12.66 |
$6,330 |
D/D |
500 |
385,575 |
2.74 |
11% |
|
| Lowe Christopher P. |
Director |
– • – |
2021-06-30 |
4 |
B |
$12.66 |
$45,576 |
D/D |
3,600 |
10,000 |
2.39 |
11% |
|
| Lee John H. |
Director |
– • – |
2021-06-29 |
4 |
B |
$12.72 |
$10,159 |
D/D |
799 |
799 |
2.39 |
16% |
|
46 Records found
|
|
Page 1 of 2 |
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
| |
OE |
- Options Exercised |
A |
- Acquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
0.17 (18.59%) 
